ANTICOAGULANTS IN ACUTE CORONARY SYNDROME
https://doi.org/10.20996/1819-6446-2009-5-3-71-75
Abstract
Clinical efficacy of unfractionated and low molecular heparins in acute coronary syndrome is discussed. New synthetic heparin derivative fondaparinux (Arixtra) is focused. Author’s brief experience of fondaparinux clinical implementation is presented.
About the Authors
I. A. Latfullin
Kazan State Medical University
Russian Federation
Russian Federation
Chair of Internal Medicine N 2
ul. Butlerova 49, 420012 Kazan, Republic Tatarstan
A. A. Podolskaya
Kazan State Medical University
Russian Federation
Russian Federation
Chair of Internal Medicine N 2
ul. Butlerova 49, 420012 Kazan, Republic Tatarstan
References
1. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Кардиоваскулярная терапия и профилактика 2007;6(8 приложение):3-66.
2. Petersen J., Mahaffey K.W., Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292(1):89-96.
3. Шалаев С.В. Низкомолекулярные гепарины в лечении нестабильной стенокардии и инфаркта миокарда без зубца Q. Consilium medicum 2002;4(3):148-50.
4. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur Heart J. 1999;20(21): 1553-62.
5. Аверков О.В. Низкомолекулярные гепарины в новых рекомендациях по ведению больных острым коронарным синдромом без стойких подъемов сегмента ST на ЭКГ. Клиническая фармакология и терапия 2008;17(1):36-40.
6. Simoons M., Bobbink I.W., Boland J. et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol 2004;43(12):2183–90.
7. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S., Mehta S.R., Chrolavicius S. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354(14): 1464-76.
8. Yusuf S., Mehta S.R., Chrolavicius S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295(13):1519–30.
Review
For citations:
Latfullin I.A., Podolskaya A.A. ANTICOAGULANTS IN ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology. 2009;5(3):71-75. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-3-71-75
Views:
690
.jpg)
Email this article 